Education
About Us
Working with TipRanks
Follow Us
Adagene (ADAG)
NASDAQ:ADAG
ADAG Stock Chart & Stats
$1.84
-$0.15(-7.28%)
At close: 4:00 PM EST
$1.84
-$0.15(-7.28%)
Day’s Range― - ―
52-Week Range$1.33 - $3.16
Previous CloseN/A
Volume1.51K
Average Volume (3M)95.04K
Market Cap
$90.02M
Enterprise Value$35.89M
Total Cash (Recent Filing)$62.83M
Total Debt (Recent Filing)$6.85M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Apr 01, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding47,109,554
10 Day Avg. Volume114,149
30 Day Avg. Volume95,041
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue347.78
Enterprise Value/Gross Profit-31.95
Enterprise Value/Ebitda-1.01
Forecast
1Y Price Target
$7.67Price Target Upside316.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical SuccessAdagene's conditionally masked CTLA-4 antagonist muzatotug (muza) is best-positioned for clinical and commercial success in relapsed/refractory microsatellite stable, non-liver metastatic colorectal cancer.
Regulatory MilestoneFDA alignment on trial design of both Phase 2 and 3 studies with ADG126 is seen as an important regulatory milestone, providing clarity on ADG126’s development path.
Strategic InvestmentAdagene announced a strategic investment of up to $25M from Sanofi, which strengthens its balance sheet to advance its proprietary pipeline.
Bears Say
Development RisksThis clinical experience meaningfully de-risks the company’s protease masking development capabilities and platform, providing underappreciated platform value and strategic optionality.
Financial SustainabilityThe company ended the quarter with $62.8M in cash and cash equivalents, which the company states should sustain operations into 2027.
Market ChallengesMuzastotug is well positioned for development and commercial success in the relapsed/refractory and earlier-line colorectal cancer settings.
Adagene News
ADAG FAQ
What was Adagene’s price range in the past 12 months?
Adagene lowest stock price was $1.32 and its highest was $3.16 in the past 12 months.
What is Adagene’s market cap?
Adagene’s market cap is $90.02M.
When is Adagene’s upcoming earnings report date?
Adagene’s upcoming earnings report date is Apr 01, 2026 which is in 167 days.
How were Adagene’s earnings last quarter?
Adagene released its earnings results on Aug 12, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$0.04.
Is Adagene overvalued?
According to Wall Street analysts Adagene’s price is currently Undervalued.
Does Adagene pay dividends?
Adagene does not currently pay dividends.
What is Adagene’s EPS estimate?
Adagene’s EPS estimate is -0.26.
How many shares outstanding does Adagene have?
Adagene has 47,109,554 shares outstanding.
What happened to Adagene’s price movement after its last earnings report?
Adagene reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -13.613%.
Which hedge fund is a major shareholder of Adagene?
Currently, no hedge funds are holding shares in ADAG
Adagene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (316.85% Upside)
$7.67 (316.85% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.74%
12-Months-Change
Fundamentals
Return on Equity
-63.41%
Trailing 12-Months
Asset Growth
-34.00%
Trailing 12-Months
Company Description
Adagene
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
ADAG Stock 12 Month Forecast
Average Price Target
$7.67
▲(316.85% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
11.77% Other Institutional Investors
88.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---